Rigel
corporate overview

pipeline

investors & media

careers



investors & media


Investor Relations Home

Rigel currently has the following product candidates in development: fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP and initiating a Phase 2 clinical trial for IgA nephropathy (IgAN); R348, a topical JAK/SYK inhibitor, in a Phase 2 clinical trial for dry eye in ocular graft-versus-host disease (GvHD); two oncology product candidates in Phase 1 development with partners BerGenBio AG and Daiichi; and two preclinical programs with partners AstraZeneca for R256 in asthma and Bristol-Myers Squibb for TGF beta inhibitors in immuno-oncology.

Webcast ImageWebcast
Rigel Pharmaceuticals Inc. at Jefferies 2015 Healthcare Conference Presentation (Live)
June 3, 2015 at 1:30 p.m. ET
Stock Quote
RIGL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.50
Change (%)0.00 (0.00%)
Volume685,925
Data as of 05/27/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
Title
2015 Q1 10-Q - PDF 
2015 Q1 10-Q
2015 Proxy Statement - PDF 
2015 Proxy Statement
2014 Annual Report - PDF 
2014 Annual Report
Financial Tear Sheet - PDF 
Financial Tear Sheet
Recent NewsMore >>
DateTitle 
05/07/15Rigel Announces First Quarter 2015 Financial Results
- Conference Call and Webcast Today at 4:30 PM Eastern Time - SOUTH SAN FRANCISCO, Calif., May 7, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2015. For the first quarter of 2015, Rigel reported a net loss of $18.2 million, or $0.21 per share, compared to a net loss of $22.3 million, or $0.25 per share, in the first quarter of 2014. Weighted average shares outstanding for the first quarters of 2015 a... 
Printer Friendly Version
04/30/15Rigel Announces Conference Call and Webcast to Report First Quarter 2015 Financial Results and Pipeline Update
SOUTH SAN FRANCISCO, Calif., April 30, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2015 financial results after market close on Thursday, May 7, 2015.  Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results and provide an update on the Company's clinical programs and pipeline. Participants can access the li... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitleRemind MePrior to Event
June 3, 2015
1:30 p.m. ET
Rigel Pharmaceuticals Inc. at Jefferies 2015 Healthcare Conference Presentation
days
Enter your e-mail address 
Most Viewed Links
Title
Updated 05/20/15
1.SEC Filings
2.Rigel Announces First Quarter 2015 Financial Results
3.Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications
4.Q1 2015 Rigel Pharmaceuticals Inc. Earnings Conference Call
5.Current Financial Reports
* Data collected 05/12/15 - 05/19/15
Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
© 2014 Rigel  |  privacy  |  disclaimer  | Follow Us On:contact us | site map |  search    Search